Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
PBE, Elizabeth Dole Foundation Exceed Goal to Benefit Veterans, Caregivers by Nearly $100,000
Ohio-based incontinence product manufacturer Principle Business Enterprises, Inc. (PBE), and the Elizabeth Dole Foundation, a Washington, DC, nonprofit that advocates for military caregivers, exceeded their joint goal for a year-long fundraising drive, with contributions totaling $295,000 to provide essential relief to these “Hidden Heroes.” Earmarked for the foundation’s “Respite Relief for Military and Veteran Caregivers” program that gives qualifying caretakers a much-needed break, the money will directly benefit an estimated 340 military families and indirectly impact more than 1000 individuals. Respite Relief recipients – spouses, parents, relatives and friends who take care of America’s wounded, ill and injured veterans – enjoy 35 hours of free help from in-home care professionals. Read more.
Source Nonwovens Industry, November 18, 2022
Urinary Tract Infections: A New Antibiotic May Be on the Way to Treat UTIs
A new type of antibiotic for treating urinary tract infections (UTIs) may be available sooner than expected. Gepotidacin, manufactured by the pharmaceutical company GSK, is being described as “novel” or “first-in-class” because of how it works to prevent or slow bacterial DNA replication. If approved, gepotidacin would be the first new antibiotic developed for treating UTIs in more than 20 years. It would also be available at least a year ahead of the estimated study completion date. Read more.
Source: healthline, November 8, 2022
BioDerm, Inc. Begins Distribution in Home Care Markets of a New Revolutionary Female Incontinence Device From TillaCare, Ltd
BioDerm is excited to partner with TillaCare as a U.S. distributor of TillaCare’s UriCap Female. UriCap Female is a revolutionary external urine collection system offering female patients with urinary incontinence a comfortable, easy-to-use solution without the skin irritation and discomfort associated with absorbent products. Following the successful launch of UriCap Female in hospital and institutional settings, BioDerm launched a direct-to-consumer campaign allowing patients to receive UriCap Female for in-home use. Read more.
Source: Index-Journal, October 28, 2022
Henkel Qhesive Solutions Reveals Promising Trial Results for Smart Adult Care
In the face of an aging population, smart technology will play a vital role in improving elder individuals’ quality of life and dignity, Henkel Qhesive Solutions has demonstrated how innovation will be helping to address the challenge of caring for those affected by incontinence: A long term trial of Smart Adult Care recently run in a nursing home in Italy has shown that digital diapers can improve the patient’s wellbeing through more timely changes, while allowing staff to focus on delivering better care. Read more.
Source: Nonwovens Industry, October 20, 2022
Neuspera Medical® Announces First Successful Implant of the Nuvella™ System in the Second Phase of Its SANS-UUI IDE Clinical Trial
Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced the first patient successfully implanted with the Nuvella™ system in its pivotal clinical trial (SANS-UUI). The procedure was performed by Dr. Jodi Michaels of Minnesota Urology, St. Paul, MN. The study will evaluate the safety and efficacy of the Nuvella system, designed to treat overactive bladder (OAB) with sacral neuromodulation (SNM) in patients with urinary urgency incontinence (UUI) symptoms. Read more.
Source: PRNewsire, October 10, 2022
Urolon, A New Treatment for Female Stress Urinary Incontinence, Launches in the UK
Stress Urinary Incontinence (SUI) is the most common type of urinary incontinence. According to estimations around 1 in 3 women will experience bladder leakage at some point in their life. SUI happens when the sphincter muscle that controls the urethra, the pelvic floor tissues and muscles that are used to keep the urethra closed, weakens. Urolon developed by Netherlands-based AQLANE Medical, is solving for this. Urolon is a bioresorbable, non-permanent filler that is completely removed from your body over time. The treatment is minimally invasive, takes around 20 minutes and can be performed in a hospital or clinic. Three small injections into the urethral wall restore its closure. Read more.
Source: FemTech Insider, October 6, 2022
What is Incontinence-Associated Dermatitis?
Incontinence-associated dermatitis (IAD) is a form of dermatitis caused by irritants that develop from chronic exposure to urine or liquid feces. Incontinence-associated dermatitis (MASD) consists of one of four types of moisture-associated skin damage. Moisture-associated skin damage has been defined as gradual inflammation and skin erosion resulting from prolonged exposure to several sources of moisture, including perspiration, wound exudate, mucus, saliva, urine, or feces. Read more.
Source: News-medical.net, September 28,2022